This website is best viewed using the horizontal display on your tablet device.
This site is intended for U.S. healthcare professionals.
Indication
IDHIFA® (enasidenib) is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation as detected by an FDA-approved test.
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.